Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance

HS Al-Malky, SE Al Harthi… - Journal of Oncology …, 2020‏ - journals.sagepub.com
Background Doxorubicin is one of the most commonly prescribed and time-tested anticancer
drugs. Although being considered as a first line drug in different types of cancers, the two …

[HTML][HTML] Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and …

B Biersack - Non-coding RNA research, 2016‏ - Elsevier
The epigenetic regulation of cancer cells by small non-coding RNA molecules, the
microRNAs (miRNAs), has raised particular interest in the field of oncology. These miRNAs …

Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy

S Wang, J Zhang, Y Wang, M Chen - … : Nanotechnology, Biology and …, 2016‏ - Elsevier
MicroRNAs (miRNAs) play critical roles in modulating the oncogenic driver pathways
involved in the acquisition of resistance to cancer treatments. MiR-542-3p serves as a potent …

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

E Tormo, S Ballester, A Adam-Artigues, O Burgués… - Scientific reports, 2019‏ - nature.com
The mechanisms of chemotherapy resistance in triple negative breast cancer remain
unclear, and so, new molecules which might mediate this resistance could optimize …

[HTML][HTML] Insights into molecular mechanisms of chemotherapy resistance in cancer

A Kar, S Agarwal, A Singh, A Bajaj, U Dasgupta - Translational Oncology, 2024‏ - Elsevier
Cancer heterogeneity poses a significant hurdle to the successful treatment of the disease,
and is being influenced by genetic inheritance, cellular and tissue biology, disease …

Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes

MS Ahmad, M Braoudaki, H Patel, I Ahmad… - Frontiers in …, 2023‏ - frontiersin.org
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …

MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN

P Ren, F Gong, Y Zhang, J Jiang, H Zhang - Tumor Biology, 2016‏ - Springer
Abstract MicroRNA-92a (miR-92a) has been reported to play important roles in
tumorigenesis of human various cancers. However, the roles and underlying molecular …

miR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene

S Safaei, M Amini, S Najjary, A Mokhtarzadeh… - Experimental and …, 2022‏ - Elsevier
Background Breast cancer (BC) has been known as the most common type of cancer
worldwide and resulted in death among women. BC is usually resistant to standard …

Combination of Metformin, Sodium Oxamate and Doxorubicin Induces Apoptosis and Autophagy in Colorectal Cancer Cells via Downregulation HIF-1α

J Coronel-Hernández, R Salgado-García… - Frontiers in …, 2021‏ - frontiersin.org
Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide in
both sexes. Current therapies include surgery, chemotherapy, and targeted therapy; …

miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux

N Jain, B Das, B Mallick - DNA repair, 2022‏ - Elsevier
Doxorubicin (Dox) is one of the most used drugs in the treatment of Soft tissue sarcoma.
However, acquired resistance linked with poor survival and numerous side effects are the …